ALK and acute myeloid leukemia: HH signaling is also involved in ovarian cancer, bladder cancer, endometrial cancer, rhabdomyosarcoma, pancreatic tumorigenesis, non-small-cell lung cancer (NSCLC), melanoma, and hematological malignancies such as acute myeloid leukemia (AML), diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL), Hodgkin’s lymphoma (HL), ALK+ anaplastic large cell lymphoma (ALCL), mantle cell lymphoma (MCL), multiple myeloma (MM) and chronic myeloid leukemia (CML) [66,107,108,109,110,111,112,113,114,115].